Oxaliplatin
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Recombinant erythropoietin
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Pembrolizumab
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Venlafaxine
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Amikacin/ciprofloxacin/cotrimoxazole
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Febuxostat/HMG-CoA-reductase-inhibitors/proton-pump-inhibitors
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Ciclosporin
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Iguratimod/Warfarin
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Prednisolone
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Tozinameran
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Pembrolizumab
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Multiple drugs
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

COVID-19-vaccine/tamoxifen
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research

Multiple drugs
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research